F
Francesca Carlomagno
Researcher at University of Naples Federico II
Publications - 96
Citations - 7588
Francesca Carlomagno is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Proto-Oncogene Proteins c-ret & Receptor tyrosine kinase. The author has an hindex of 40, co-authored 93 publications receiving 7101 citations. Previous affiliations of Francesca Carlomagno include National Research Council & Maharaja Sayajirao University of Baroda.
Papers
More filters
Journal ArticleDOI
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
Massimo Santoro,Francesca Carlomagno,A Romano,Donald P. Bottaro,Nina A. Dathan,M. Grieco,Alfredo Fusco,Giancarlo Vecchio,B Matoskova,Matthias H. Kraus +9 more
TL;DR: Oncogenic conversion of RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.
Journal Article
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno,Donata Vitagliano,Teresa Guida,Fortunato Ciardiello,Giampaolo Tortora,Giancarlo Vecchio,Anderson J. Ryan,Gabriella Fontanini,Alfredo Fusco,Massimo Santoro +9 more
TL;DR: ZD6474, a low molecular weight tyrosine kinase inhibitor, blocks the enzymatic activity of RET-derived oncoproteins at a one-half maximal inhibitory concentration of 100 nM and might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET.
Journal ArticleDOI
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Francesca Carlomagno,Suresh Anaganti,Teresa Guida,Giuliana Salvatore,Giancarlo Troncone,Scott Wilhelm,Massimo Santoro +6 more
TL;DR: BAY 43-9006 is a powerful inhibitor of the RET kinase and its potential as a therapeutic tool for RET-positive thyroid tumors, including those expressing V804 mutations merits study.
Journal ArticleDOI
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
M Santoro,Francesca Carlomagno,Ian D. Hay,M A Herrmann,M Grieco,Rosa Marina Melillo,Marco A. Pierotti,Italia Bongarzone,G. Della Porta,N Berger +9 more
TL;DR: This work found the presence of an activated form of the ret oncogene in 33 (19%) of 177 papillary carcinomas, and none of the other 109 thyroid tumors, which included 37 follicular, 15 anaplastic, and 18 medullary carcinoma, and 34 benign lesions, showed ret activation.
Journal Article
Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase
Fortunato Ciardiello,Rosa Caputo,Vincenzo Damiano,Roberta Caputo,Teresa Troiani,Donatella Vitagliano,Francesca Carlomagno,Bianca Maria Veneziani,Gabriella Fontanini,A. Raffaele Bianco,Giampaolo Tortora +10 more
TL;DR: This study suggests that in addition to inhibiting endothelial cell proliferation by blocking VEGF-induced signaling, ZD6474 may also be able to inhibit cancer cell growth by blocking EGFR autocrine signaling.